GANGLIONIC blockade, though an effeetive method of lowering blood pressure in hypertensive patients, is frequently accompanied by many unpleasant effects attributable to blockade of the parasympathetic nervous system. These side effects limit the reduction in blood pressure practicably attainable. 1 The development of a new hypotensive agent that reduces sympathetic nervous discharge without inhibiting parasympathetic activity has provided a promising approach to the management of hypertensive vascular disease. This drug, which has the chemical structure shown below Eleven patients have been fol to 6 months after discharge from These patients all had severe disease (7 IDenotes differences significant at the p <.05 level. treatment, the difference was not statistically significant.
Insofar as the changes in calculated total peripheral resistance can be assumed to represent changes in the average caliber of arterioles,7 it appears that reduction in blood pressure accompanying guanethidine administration is not brought about by relaxation of arteriolar constriction, since peripheral resistance decreased only slightly. Thus guanethidine, like ganglionic-blocking drugs8 9 presumably lowers blood pressure by reduction in cardiac output, possibly by inhibition of syirpathetic venoconstrictor mechanisms with resultant pooling of blood in peripheral veins, especially in the standing position. The orthostatic hypotension and reduction in pulse pressure accompanying the use of guanethidine support the view that pooling of blood in leg veins with decrease in venous return and hence in cardiac output is responsible for the reduction in blood pressure. There is no direct evidence from the available data, however, that eliminates the alternate hypothesis that guanethidine primarily affects myocardial contractility rather than venous return.
As shown in up tilt to 40' reduced Cl,, and CPAH by about 30 per cent, despite lack of significant change in blood pressure. Administration of guanethidine was accompanied by reduction in GFR and RPF in both lying and "standing" positions in 7 individuals. These measurements were unchanged in 3 and rose slightly in 1. Blood pressure decreased proportionately more than did renal plasma flow, so that calculated renal vascular resistance diminished slightly as compared to pretreatment values in either position. This slight deerease in renal vascular resistance was minor in comparison with the reductioni in the absolute values for glomerular filtration rate and renal plasma flow aceompanying administration of the drug. During guanethidine treatment, GFR averaged one third and RPF one fourth of the pretreatment values in the "standing" (40°tilted) position. Filtration fraction, the ratio of GFR to RPF, decreased under the influenee of guanethidine, indicating proportionately greater fall in filtration than in blood flow. This observation suggests that the reduction in arterial pressure is primarily re- 
Summario in Interlingua
Guanethidina-un nove droga hypotensive synthetic que probabilemente inhibi le liberation de norepinephrina per le terminos sympathico-nervose e que demonstratemente non inhibi le activitate parasympathic-se ha provate capace a efficacemente reducer le tension del sanguine in 25 patientes hypertensive qui esseva studiate durante periodos de usque a 6 menses. Le adverse effectos lateral esseva restringite a hypotension orthostatic e leve grados de diarrhea.
Apparentemente le droga reduce le tension del sanguine per reducer le rendimento cardiac plus tosto que per relaxar le arteriolas. Le administration del droga esseva accompaniate de reductiones in le fluxo de sanguine renal e in le intensitate del filtration glomerular, sed azotemia progressive o oliguria non oceurreva in ulle del casos.
Iste agente es un potentissime droga hypotensive. Le duration de su effecto es remareabilemente longe. Illo es characterisate per nulle del effectos lateral parasympatholytic que es producite per le agentes de blocage ganglionic.
